Men with metastatic castration-sensitive prostate cancer continue to derive a survival benefit from the addition of apalutamide to androgen deprivation therapy, suggest long-term data from the TITAN trial.

Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer derive a significant radiographic progression-free survival benefit from the addition of apalutamide to abiraterone acetate, suggest phase 3 trial data.

Further analysis of patients with nonmetastatic castration-resistant prostate cancer from the SPARTAN trial has identified molecular biomarkers associated with long-term responses to apalutamide.

Felix Feng discusses the implications of identifying molecular biomarkers of response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Study author Axel Merseburger takes us through the TITAN trial investigating the addition of apalutamide to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting, and also addresses the key question of how physicians should choose between the available treatment options (3:03).

Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.

Supplementing androgen deprivation therapy with apalutamide improves metastasis-free survival in patients with the luminal and basal subtypes of nonmetastatic castration-resistant prostate cancer, indicates an analysis of the randomized SPARTAN trial.

Men with high-risk nonmetastatic castration-resistant prostate cancer do not report a deterioration in health-related quality of life when androgen deprivation therapy is supplemented with apalutamide, indicate SPARTAN trial results.

Further analysis showed that the increased risk for neurocognitive ADRs with novel ARSIs was driven by enzalutamide as opposed to apalutamide or abiraterone.

The exploratory pooled analysis included the 4117 participants of the placebo-controlled PROSPER, SPARTAN, and ARAMIS trials that evaluated the second-generation ARIs enzalutamide, apalutamide, and darolutamide, respectively, in nonmetastatic CRPC patients with a prostate-specific antigen level of at least 2.0 µg/L and a doubling time of 10 months or less.

This was also the case for second-generation ARAs (eg, enzalutamide and apalutamide) and the androgen synthesis inhibitor abiraterone acetate, with respective RORs of 0.80 and 0.87 versus GnRH agonists, but there were significantly more reports for first-generations ARAs (eg, bicalutamide), with an ROR of 1.23.

Abiraterone acetate or apalutamide given in combination with androgen deprivation therapy offer the best survival outcomes for patients with metastatic castration-sensitive prostate cancer, a network meta-analysis shows.

Axel Merseburger discusses the key abstracts in the 2021 Genitourinary Cancers Symposium prostate cancer track, including TITAN, TheraP, and ACIS, and shares his thoughts on how these findings may inform clinical practice.

The rates of all-grade falls and fractures differed by ARI type, with the highest incidence seen with apalutamide, at 12.0% and 10.0%, respectively, followed by enzalutamide (8.0 and 1.8%, respectively) and darolutamide (4.2 and 4.2%, respectively).